CYTOKINETICS (CYTK) CEO Robert Blum Exercises Options, Sells Shares

What Happened

• Robert I. Blum, President & CEO and a director of Cytokinetics, exercised 7,490 option-derived shares at $10.60 per share (cost $79,394) on 2026-07-13 and immediately sold those 7,490 shares in an open-market transaction at $82.02 per share for gross proceeds of $614,330. The net proceeds from the exercise-and-sale are roughly $534,936 before taxes and fees.
• On the same day he also sold 10 shares in an open-market transaction at $82.02 for $820.
• These filings show an option exercise/conversion entry (derivative) recorded at $0, which reflects conversion/exercise bookkeeping of the derivative instrument.

Key Details

• Transaction date: 2026-07-13; filing date: 2026-07-14 (filed timely).
• Option exercise: 7,490 shares exercised at $10.60 (total cost $79,394).
• Sale: 7,490 shares sold at $82.02 (gross proceeds $614,330); additional 10-share sale for $820.
• Shares owned after transaction: not specified in the provided filing details.
• Footnotes: F1 — shares held by The Bridget Blum 2003 Irrevocable Trust; F2 — shares held by The Brittany Blum 2003 Irrevocable Trust.
• Transaction codes: M = option exercise; S = sale. The pattern (exercise followed by immediate sale) indicates a cashless or sell-to-cover style transaction.

Context

• When an insider exercises options and sells the resulting shares the same day, it is commonly a cashless exercise or sell-to-cover to realize value or cover option costs/taxes; this is a routine liquidity event and not necessarily a signal of company outlook.
• The filing is timely (next-business-day), and the derivative entries simply document the exercise/conversion of option rights into common shares.